Bayer Full-Year Report 2023

Highlights

• Group sales: €47.6 billion (Fx & p adj. −1.2%), currency headwinds of around €2 billion.
• EBITDA before special items falls to €11.7 billion (-13.4%).
• Crop Science records significant decline in sales and earnings against very strong prior year, mainly due to lower glyphosate prices.
• Pharmaceuticals registers stable sales (Fx & p adj.), lower earnings.
• Consumer Health continues positive business performance.
• Core earnings per share at €6.39 (-19.5%).
• Net income: minus €2.9 billion, weighed down by impairments at Crop Science.